Haemonetics Corporation
HAE
$81.35
$0.600.74%
NYSE
| 09/27/2025 | 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.27% | -4.40% | -3.70% | 3.66% | 8.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.27% | -4.40% | -3.70% | 3.66% | 8.59% |
| Cost of Revenue | -14.00% | -17.43% | -14.84% | -1.78% | 4.53% |
| Gross Profit | 1.78% | 7.01% | 5.41% | 8.10% | 12.10% |
| SG&A Expenses | -4.70% | -1.41% | 1.36% | -0.34% | -2.80% |
| Depreciation & Amortization | -8.82% | -8.65% | 8.35% | 76.96% | 69.81% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.53% | -10.08% | -6.86% | 1.87% | 3.70% |
| Operating Income | 15.12% | 27.38% | 15.10% | 12.07% | 40.21% |
| Income Before Tax | 14.72% | -3.31% | 202.11% | 13.37% | 36.16% |
| Income Tax Expenses | 15.89% | 33.55% | 318.64% | -2.85% | 37.22% |
| Earnings from Continuing Operations | 14.34% | -11.32% | 184.68% | 20.02% | 35.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.34% | -11.32% | 184.68% | 20.02% | 35.82% |
| EBIT | 15.12% | 27.38% | 15.10% | 12.07% | 40.21% |
| EBITDA | 9.08% | 16.95% | 14.51% | 15.28% | 35.28% |
| EPS Basic | 22.30% | -6.11% | 193.92% | 21.16% | 35.38% |
| Normalized Basic EPS | 24.83% | 2.77% | 5.16% | 0.87% | 30.99% |
| EPS Diluted | 22.73% | -5.41% | 194.65% | 21.31% | 37.50% |
| Normalized Diluted EPS | 25.48% | 3.52% | 5.83% | 1.52% | 31.80% |
| Average Basic Shares Outstanding | -6.50% | -5.56% | -3.14% | -0.95% | 0.34% |
| Average Diluted Shares Outstanding | -6.98% | -6.23% | -3.76% | -1.57% | -0.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |